MAF

Across TCGA pan-cancer cohorts, MAF mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAF data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAF expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where MAF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.636	0.247	.014	13	view →
PDAC	OS	Median	All	0.212	0.748	.019	10	view →
UCEC	DFS	Tertile	All	0.373	1.000	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAF–CCRCC (DFS)

Open the CCRCC breakdown →